Briacell Therapeutics Corp Financials
Financial Health Signals
Briacell Therapeutics Corp passes 2 of 9 financial strength tests. No profitability signals pass, 2 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Briacell Therapeutics Corp generates $1.07 in operating cash flow (-$28.2M OCF vs -$26.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Briacell Therapeutics Corp earns $-735.7 in operating income for every $1 of interest expense (-$27.2M vs $37K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Briacell Therapeutics Corp (BCTXZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Briacell Therapeutics Corp's EBITDA was -$27.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 18.5% from the prior year.
Briacell Therapeutics Corp reported -$26.3M in net income in fiscal year 2025. This represents a decrease of 449.1% from the prior year.
Briacell Therapeutics Corp earned $-62.19 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 42.4% from the prior year.
Briacell Therapeutics Corp held $2.7M in cash against $0 in long-term debt as of fiscal year 2025.
Briacell Therapeutics Corp had 2M shares outstanding in fiscal year 2025. This represents a decrease of 94.8% from the prior year.
Briacell Therapeutics Corp invested $21.3M in research and development in fiscal year 2025. This represents a decrease of 21.7% from the prior year.
BCTXZ Income Statement
| Metric | Q1'25 | Q3'25 | Q2'25 | Q1'24 | Q2'24 | Q3'24 | Q1'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $6.7M+38.9% | $4.8M-15.4% | $5.7M+55.1% | $3.7M-55.6% | $8.3M+7.8% | $7.7M+11.7% | $6.9M+124.6% | $3.1M |
| SG&A Expenses | $1.6M+8.0% | $1.5M+2.2% | $1.5M-0.2% | $1.5M-5.4% | $1.6M0.0% | $1.6M-4.5% | $1.6M+14.9% | $1.4M |
| Operating Income | -$8.3M-31.5% | -$6.3M+11.7% | -$7.2M-39.1% | -$5.2M+47.6% | -$9.8M-6.5% | -$9.2M-8.5% | -$8.5M-89.5% | -$4.5M |
| Interest Expense | N/A | $37K | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$8.2M-33.8% | -$6.1M+2.6% | -$6.3M-8.4% | -$5.8M+48.6% | -$11.3M-758.3% | $1.7M-71.4% | $6.0M+150.5% | -$11.9M |
| EPS (Diluted) | $-4.35-165.2% | $-1.64 | $-2.33+92.9% | $-32.67-207.0% | $-10.64-760.9% | $1.61+422.0% | $-0.50+35.1% | $-0.77 |
BCTXZ Balance Sheet
| Metric | Q1'25 | Q3'25 | Q2'25 | Q1'24 | Q2'24 | Q3'24 | Q1'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $13.1M-23.1% | $17.0M+81.6% | $9.4M-10.1% | $10.4M+77.3% | $5.9M-5.3% | $6.2M-66.7% | $18.6M-31.5% | $27.2M |
| Current Assets | $11.3M-23.2% | $14.8M+106.4% | $7.2M-12.9% | $8.2M+124.9% | $3.7M-33.9% | $5.5M-70.0% | $18.4M-31.7% | $26.9M |
| Cash & Equivalents | $2.7M-78.2% | $12.5M+148.5% | $5.0M-13.4% | $5.8M+571.9% | $862K-7.9% | $936K-93.1% | $13.6M-35.8% | $21.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | $30K+97.9% | $15K-28.9% | $21K+13.4% | $19K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.7M-26.4% | $5.1M-17.5% | $6.1M-8.4% | $6.7M-21.7% | $8.6M-31.2% | $12.4M-22.8% | $16.1M-48.0% | $30.9M |
| Current Liabilities | $3.3M-23.4% | $4.3M-17.2% | $5.2M+4.9% | $5.0M-33.1% | $7.5M+10.4% | $6.8M+545.7% | $1.0M-41.9% | $1.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $9.4M-21.7% | $11.9M+270.1% | $3.2M-13.1% | $3.7M+238.3% | -$2.7M+56.9% | -$6.2M-347.7% | $2.5M+166.6% | -$3.8M |
| Retained Earnings | -$120.0M-15.7% | -$103.7M-6.3% | -$97.5M-6.9% | -$91.2M-6.8% | -$85.4M-1.4% | -$84.2M-12.8% | -$74.7M+7.4% | -$80.7M |
BCTXZ Cash Flow Statement
| Metric | Q1'25 | Q3'25 | Q2'25 | Q1'24 | Q2'24 | Q3'24 | Q1'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.7M-7.6% | -$7.2M-21.0% | -$5.9M+14.9% | -$7.0M-72.3% | -$4.0M+20.6% | -$5.1M+33.2% | -$7.6M+30.3% | -$10.9M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$75K+28.6% | -$105K-40.0% | -$75K0.0% | -$75K+83.6% | -$457K | N/A | N/A | N/A |
| Financing Cash Flow | $13.6M-7.9% | $14.7M+182.1% | $5.2M-56.4% | $12.0M | N/A | N/A | N/A | $4.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
BCTXZ Financial Ratios
| Metric | Q1'25 | Q3'25 | Q2'25 | Q1'24 | Q2'24 | Q3'24 | Q1'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | 238.5% | N/A |
| Return on Assets | -62.7%-26.7pp | -36.0%+31.2pp | -67.2%-11.5pp | -55.7%+36.6pp | -92.3%-120.0pp | 27.7%-4.6pp | 32.2%+67.0pp | -34.8% |
| Current Ratio | 3.420.0 | 3.41+2.0 | 1.37-0.3 | 1.65+1.2 | 0.49-0.3 | 0.82-16.8 | 17.59+2.6 | 14.96 |
| Debt-to-Equity | 0.40-0.0 | 0.42-1.5 | 1.90+0.1 | 1.80+5.0 | -3.19-1.2 | -2.00-8.4 | 6.40+14.6 | -8.19 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Briacell Therapeutics Corp profitable?
No, Briacell Therapeutics Corp (BCTXZ) reported a net income of -$26.3M in fiscal year 2025.
What is Briacell Therapeutics Corp's earnings per share (EPS)?
Briacell Therapeutics Corp (BCTXZ) reported diluted earnings per share of $-62.19 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Briacell Therapeutics Corp's EBITDA?
Briacell Therapeutics Corp (BCTXZ) had EBITDA of -$27.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Briacell Therapeutics Corp's operating cash flow?
Briacell Therapeutics Corp (BCTXZ) generated -$28.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Briacell Therapeutics Corp's total assets?
Briacell Therapeutics Corp (BCTXZ) had $13.1M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Briacell Therapeutics Corp spend on research and development?
Briacell Therapeutics Corp (BCTXZ) invested $21.3M in research and development during fiscal year 2025.
How many shares does Briacell Therapeutics Corp have outstanding?
Briacell Therapeutics Corp (BCTXZ) had 2M shares outstanding as of fiscal year 2025.
What is Briacell Therapeutics Corp's current ratio?
Briacell Therapeutics Corp (BCTXZ) had a current ratio of 3.42 as of fiscal year 2025, which is generally considered healthy.
What is Briacell Therapeutics Corp's debt-to-equity ratio?
Briacell Therapeutics Corp (BCTXZ) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Briacell Therapeutics Corp's return on assets (ROA)?
Briacell Therapeutics Corp (BCTXZ) had a return on assets of -201.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Briacell Therapeutics Corp's cash runway?
Based on fiscal year 2025 data, Briacell Therapeutics Corp (BCTXZ) had $2.7M in cash against an annual operating cash burn of $28.2M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Briacell Therapeutics Corp's Piotroski F-Score?
Briacell Therapeutics Corp (BCTXZ) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Briacell Therapeutics Corp's earnings high quality?
Briacell Therapeutics Corp (BCTXZ) has an earnings quality ratio of 1.07x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Briacell Therapeutics Corp cover its interest payments?
Briacell Therapeutics Corp (BCTXZ) has an interest coverage ratio of -735.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.